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Abstract
The fraction of intact monomer in a sample (moles/moles), the monomeric purity, is measured as a quality control in therapeutic
monoclonal antibodies but is often unknown in research samples and remains a major source of variation in quantitative
antibody-based techniques such as immunoassay development. Here, we describe a novel multiplex technique for estimating
the monomeric purity and antigen affinity of research grade antibody samples. Light scattering was used to simultaneously
observe themass of antibody binding to biosensor surfaces functionalised with antigen (revealing Fab binding kinetics) or protein
A/G (PAG). Initial estimates of monomeric purity in 7 antibody samples including a therapeutic infliximab biosimilar were
estimated by observing a mass deficit on the PAG surface compared to the NISTmAb standard of high monomeric purity.
Monomeric purity estimates were improved in a second step by observing the mass of antigen binding to the mass of antibody
on the PAG surface. The NISTmAb and infliximab biosimilar displayed tightly controlled stoichiometries for antigen binding of
1.31 ± 0.57 and 1.71 ± 0.16 (95% confidence interval)—within the theoretical limit of 1–2 antigens per antibody depending on
avidity. The other antibodies in the panel displayed antigen binding stoichiometries in the range 0.06–1.15, attributed to lower
monomeric purity. The monomeric purity estimates were verified by electrospray ionization mass spectrometry (ESI), the gold
standard technique for structural characterization of antibodies. ESI data indicated that the NISTmAb and infliximab biosimilar
samples had monomeric purity values of 93.5% and 94.7%, respectively, whilst the research grade samples were significantly
lower (54–89%). Our results demonstrate rapid quality control testing for monomeric purity of antibody samples (< 15 min)
which could improve the reproducibility of antibody-based experiments.
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Introduction
In non-therapeutic antibodies used for research, a link has
been made between poor reproducibility of results and
variability in antibody quality [1–3]. Antibody samples are
known to undergo degradation over time during storage [4]
and in vivo and the fraction of intact monomer in a sample, the
monomeric purity, is tested to ensure potency of therapeutic
antibodies [5]. Antibodies for research should also be assessed
for monomeric purity to ensure reproducible experiments [6]
and a rapid technique for assessing the monomeric purity of
antibody samples could test the extent of degradation in sam-
ples immediately before use.
Lot-to-lot comparisons of antibody samples should be per-
formed with reference standards [7]. The National Institute of
Standards and Technology (NIST) provides a monoclonal anti-
body, the NISTmAb, designed to support biopharmaceutical in-
novation by serving as reference standard for comparable eval-
uation of antibody-based techniques between different laborato-
ries [8–10]. The NISTmAb is a recombinant humanized IgG1ĸ
with a known sequence [11] specific to the respiratory syncytial
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virus protein F (RSVF) [12]. The NISTmAb is well character-
ized with a known monomeric purity variation of 96.7–98.7%
between batches, as characterized by comparing the relative
peak areas of a non-denaturing size exclusion chromatogram
[8, 9]. The NIST 8671 certificate for the material used in the
present study quotes a monomeric purity of 96.63 ± 0.46%.
Fragmentation in monoclonal antibody samples is fre-
quently observed at the hinge region disulphide bonds. In this
region, a single polypeptide connects the Fab and Fc frag-
ments and hence cleavage is followed by separation of these
fragments [13]. The most abundant antibody fragments and
their respective masses observed by non-denaturing size ex-
clusion chromatography (SEC) [4] are shown in Fig. 1a.
SEC, sodium dodecyl sulphate-polyacrylamide gel electro-
phoresis (SDS-PAGE), andmass spectrometry (MS) are the gold
standard techniques used for characterization and stability as-
sessment of antibodies [4, 14, 15]. Non-reducing SDS-PAGE
analysis of a papain digestion of the NISTmAb shows bands
for Fab and Fc fragments at 50 kDa, whilst under reducing
conditions, the disulphide bonds between heavy and light chains
are separated to produce two species of 25 kDa [16]. The prima-
ry amino acid sequence and structure of antibodies are readily
confirmed by liquid chromatography and mass spectrometry
(LC-MS/MS) [17]; however, there are no easy methods to es-
tablish the monomeric purity or biological activity of a sample
immediately before use. Therefore, in the current study, we con-
sider the role of a multiplexed plasmonic biosensor-based assay
for rapid monitoring of antibody monomeric purity in a research
setting with similar analysis times to MS.
Plasmonic biosensors are typically used to observe antibody
binding kinetics and are fundamentally mass sensors. Accurate
kinetic parameters may be derived using antibody samples of
high monomeric purity, careful tethering chemistry, and fitting
of a mathematical kinetic model to multiple low-concentration
interactions simultaneously in a global fit [18, 19]. However,
kinetic analyses are fundamentally limited by unknown antibody
concentration and monomeric purity. The presence of multiple
binding interactions in fragmented antibody samples invalidates
the assumed Langmuirian 1:1 binding interactionmodel which is
commonly fit to plasmonic data [18].
Fig. 1 Schematic of fragmentation patterns of a typical IgG and their
binding properties: a structure of IgG. Variable and constant domains
are marked V and C with subscripts for light and heavy chain marked L
or H. Heavy chain regions are numbered 1, 2, and 3 starting from the N-
terminus and black lines indicate disulphide bonds. The most abundant
antibody fragments recorded in IgG samples and their respective molec-
ular masses are also shown. Heavy chain and light chain fragments are
labelled Hc and Lc. The 50 kDa fragment may originate from the Fab
region as shown or the Fc region. Similarly, the 25 kDa fragment may
originate from the Lc as shown, the Hc of the Fab region, or Hc of the Fc
region. b Biophotonic assays used to characterize the monomeric purity
of an IgG sample. The Fab assay uses a sensor surface functionalised with
antigen (orange) to confirm antibody specificity and derive antibody-
antigen binding kinetics. The Fc assay uses a sensor surface
functionalised with PAG (blue) to capture Fc fragments. Antibody cap-
tured by the Fc assay is used as an antigen assay to determine the
antibody-antigen binding stoichiometry. Intact IgGmay bind a maximum
of 2 antigens (orange circles), whereas samples containing fragments
lacking Fab regions will show a lack of antigen capture. The sensor
response of the antigen surface (orange) and PAG surface (blue) to the
NISTmAb is shown, with and without the inclusion of the antigen assay
step (solid and dotted lines respectively) to highlight the signal of antigen
capture
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In this paper, we report a novel multiplex technique to
simultaneously assess antibody affinity and monomeric puri-
ty, based on our in-house biosensor platform [19, 20]. Sensor
surfaces are functionalised with either antigen or the Fc bind-
ing protein A/G (PAG) to generate assays for Fab and Fc
fragments. PAG has 3 sterically available binding sites for
the Fc region of intact IgG and binds with high affinity to
antibodies from several species [20]. The technique described
here is comprised of two steps, shown in Fig. 1. In the first
step, antibody binding to the Fab assay provides data for ki-
netic analysis of the antibody-antigen interaction and the mass
of antibody binding to the Fc assay is recorded simultaneous-
ly. For a constant number of binding sites on the Fc assay
surface, an initial estimate of monomeric purity may be ob-
tained by observing a mass deficit in degraded samples com-
pared to the NISTmAb. In the second step, the mass of antigen
which can bind to the antibodies immobilized on the PAG
surface (an antigen assay) is recorded. The stoichiometry of
the antibody-antigen binding reaction on the PAG surface is
derived from the masses of antibody and antigen, and samples
with high monomeric purity should bind an average of 1–2
antigens per antibody, whereas antibody fragments lacking
Fab regions should display a lower stoichiometry. A panel of
eight antibody samples was tested: the NISTmAb, a therapeu-
tic infliximab biosimilar, and six commercially available
monoclonal and polyclonal samples for research use. Our re-
sults are validated with native ESI-quadrupole time-of-flight
(QTOF) mass spectrometry—a gold standard technique for
assessing the relative abundance of antibody fragmentation
products in a sample [21].
Materials and methods
Pierce recombinant protein A/G (#21186) and anti-C5a C17/5
(#GAU025-05-02) were obtained from Thermo Scientific.
Bovine serum albumin (BSA) (#A7030) was obtained from
Sigma-Aldrich. NIST RM 8671 was purchased from the
National Institute of Standards and Technology and respirato-
ry syncytial virus protein F (RSVF, #11049-V08B) was ob-
tained from Sino Biological Inc. C5a protein (#A145) was
purchased from Complement Technologies Inc. Anti-CRP
monoclonal, anti-CRP polyclonal, anti-TBG, TNFα, CRP,
and TBG were all obtained from a major research reagent
provider. Infliximab was obtained from clinical storage,
reflecting the conditions of therapeutic antibodies before use.
Standard instrument running buffer and sample dilution buffer
was phosphate-buffered saline (PBS) supplied in tablet form
by Sigma-Aldrich. Ortho-phosphoric acid (85%) was obtain-
ed from Fluka and a 0.01 M aqueous solution used as regen-
eration buffer. The absorbance of the NISTmAb and other
antibody samples was measured at 280 nm with a NanoDrop
instrument and converted to total protein concentration using
Beer ’s Law and a molar extinction coefficient of
210,000 M−1 cm−1 (as recommended by the manufacturer).
The binding kinetics and monomeric purity of 8 antibody
samples was assessed using our novel biophotonic
multiplexed biosensor platform, described in detail elsewhere
[19, 20, 22]. Briefly, gold nanoparticles are printed onto an
aminated glass surface using an inkjet printer and the nano-
particles are chemically grown on the surface to ~60 nm in
diameter. The gold nanoparticles are illuminated in a total
internal reflection configuration with the localized nanoparti-
cle plasmon scattering light normal to the surface depending
on the refractive index (mass) of protein in the plasmon field.
The scattered light intensity is monitored in real time using a
video camera capturing data at 30 frames per second.
A multiplexed biophotonic array is fabricated by
functionalising each of the 150 array spots with proteins using
EDC/NHS coupling chemistry [22]. The array contains some
reference spots functionalised with BSA which are used to
correct for variations in light intensity, temperature, and non-
specific binding during the time course of the experiment.
Spots functionalised with antigen are used for specific anti-
body capture via the Fab region (a Fab assay) and spots
functionalised with PAG are used for antibody capture via
the Fc region (an Fc assay). PAG binds to IgG in an orientation
presenting the Fab regions away from the sensor surface into
the solution, as seen in affinity column chromatography. Once
loaded with a given antibody, the PAG surface may be used to
capture antigen from a sample (an antigen assay).
A multiplexed array was printed with the Fc and Fab as-
says: PAG and antigen were printed with 23 repeats each from
1 mg/mL solutions in PBS. The control assay elements are
printed with 25 repeats from a 1 mg/mL solution of BSA in
PBS. The responses of assay elements were averaged to im-
prove the signal-to-noise ratio and eliminate the effects of any
inhomogeneous protein tethering density. The array surface
was blocked with BSA (1 mg/mL, 300 s) before use to min-
imize non-specific binding. The response of each assay to
refractive index (RI) change was calibrated with a step change
in running buffer from PBS to 2 × PBS concentration with a
known bulk RI change of 1.6 mRIU. The mean limit of de-
tection per individual sensor element was 6.6 (± 2.9) × 10−2
mRIU.
The Fc assay is calibrated on each array by injecting the
NISTmAb at concentrations of 1.56, 3.23, and 6.25 nM and
the response of the Fc and Fab assays recorded simultaneous-
ly. The data were used for kinetic analysis of the NISTmAb
with a global fit to the Langmuir adsorption isotherm [19, 20].
The arrays were regenerated with a 0.01 M solution of phos-
phoric acid for 100 s between samples. The PAG surface has
been demonstrated previously to be stable over > 20 regener-
ation cycles [20]. For monomeric purity testing, all antibody
samples were diluted to 100 nM (based on manufacturer stat-
ed concentration) and injected over the assay surface for a
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fixed period of 300 s to monitor association kinetics to the Fab
assay and Fc assay. The assays were washed in PBS running
buffer for 500 s to monitor dissociation kinetics. Each antigen
sample was prepared at 100 nM in PBS and injected over the
assay surfaces for 300 s to observe antigen capture by IgG
previously loaded on the PAG surface.
The sensor response to antibody or antigen binding at max-
imum surface coverage, ϑm, was derived for all experiments
with kinetic fitting of the Langmuir adsorption isotherm. All
parameters estimated from kinetic fitting are presented with
their associated 95% confidence interval derived from the co-
variance matrix of the fit. For clarity, the ϑmvalue of the Fab
assay is written ϑm Fab and the ϑmvalue of the Fc assay simi-
larly ϑm Fc. The ϑmvalue of the antigen assay is termed
ϑm antigen. To minimize experimental variation, all antibody
samples were tested in duplicate and in random sequence on
a single multiplex array of assay surfaces. The coefficient of
variation (CV) of ϑm Fc for the NISTmAb was 7%.
The LC-MS analysis was conducted using an HPLC-Chip
Cube system coupled to a 6520 quadrupole time-of-flight
(QTOF) mass spectrometer (Agilent Technologies, Santa Clara,
CA) operated in electrospray ionization (ESI) positive-ion mode.
Liquid chromatography was performed using a Protein-Chip (II)
with a 40 nL enrichment column and analytical column of
43 mm× 75 μM with Zorbax 300SB-C8 packing material at
5 μm (G4240-63001, Agilent, Santa Clara, CA). The
ChipCube source was operated at 365 °C with 5 L/min nitrogen
drying gas, the capillary voltage was set to 2100 V and
fragmentor at 400 V. The TOF MS acquisition range was from
100 to 4000 mass-to-charge ratio (m/z) at 13586 transients per
summed spectra. The source was interfaced with an Agilent
1260/1200 series HPLC system consisting of a 1260 Cap pump,
1200 Nano pump, 1200 Micro WPS, and 1290 Infinity
Thermostat (Agilent). Between 0.2 and 1 μL sample, without
dilution or additional preparation, was injected onto the enrich-
ment column using the capillary pump flow with H2O + 0.1%
formic acid (FA) at a flow rate of 4 μL/min. The sample was
eluted onto the analytical column at a flow rate of 0.6 μL/min.
Solvent A and B consisted of H2O + 0.1% formic acid (FA) and
ACN:H2O 90:10 with 0.1% FA respectively. Gradient steps are
as follows: 0–4 min from 3% B to 50% B, 4–5 min to 100% B,
5–11min 100%B, 11–12min from 100% to 3%B. Internal lock
mass calibration was performed using one calibration reference
mass at 1221.9906 m/z. Data processing was performed using
the Masshunter Workstation software version B.50.00 (Agilent).
The mass spectra of each antibody sample are averaged from
triplicate injections derived from two independent experiments.
The ESI-QTOF experiments analysed native, intact forms of
the antibodies. The raw MS data undergoes a zero-charge con-
volution in which the area contribution of each respective
charge state is summed [23]. We expressed the degree of anti-
body degradation as a relative area ratio of the light or heavy
chain combinations compared to intact protein in the
deconvoluted spectra. As we are relating relative area ratios of
the same antibody in each sample, the ionization efficiency and
therefore relative abundance estimates are expected to be inter-
nally consistent.
Results
A series of kinetic traces was recorded for each antibody sam-
ple for the Fc, Fab, and antibody-antigen assays. The data are
fitted to a Langmuir model with integrated rate equations giv-
en by Eq. 1 for the association phase and Eq. 2 for the disso-
ciation phase:
ϑ tð Þ ¼ ϑm ka P½ ka P½  þ kd 1−e
− ka P½ þkdð Þt
 
ð1Þ
ϑ tð Þ ¼ ϑae−kdt ð2Þ
where ϑ(t) is the sensor response at time, t, ϑm as before, ϑa is
the sensor response at the start of the dissociation phase, ka is
the association rate constant, kd is the dissociation rate con-
stant, and [P] is the concentration of the protein in solution
whether Fc, Fab, or antigen. All of the parameters in Eqs. 1
and 2 are highly correlated when fitted to the data of a single
concentration. However, the binding rate constants ka and kd
may be determined by fitting the model to multiple, low-
concentration samples simultaneously [19]. Furthermore, the
ϑm can be determined from replicates of a high concentration
sample (100 nM) binding over a time sufficient to achieve
near-maximum surface coverage. Simultaneous low-
concertation kinetic trace fitting and independent determina-
tion of ϑm give the most accurate determination of the inter-
action parameters in the Langmuir model.
The ϑm of the NISTmAb sample binding via the Fab region
to its antigen (RSVF) immobilized on the sensor surface was
derived as 1.73 (± 0.03) mRIU by fitting the Langmuir model
to data from 100 nM antibody samples. The kinetic parame-
ters for the NISTmAb–RSVF interaction were derived as k-
a = (8.9 ± 0.2) × 10
4 M−1 s−1, kd = (2.4 ± 0.6) × 10
−4 s−1, and
KD = 2.7 ± 0.7 nM by fitting the Langmuir model to 3 low-
concentration samples (Fig. 2). The uncertainties are derived
from the covariance matrix of the fit and are stated as 95%
confidence intervals.
The ϑm of the NISTmAb sample binding to PAG on the
sensor surface was derived as 6.7 ± 1.0 mRIU by fitting the
Langmuir model to data from 100 nM antibody samples.
Deviations from 1:1 Langmuir kinetics were evident in the
data however a global fit to four low concentrations, whilst
enabling the ϑm value to float, enables the model to fit well
and estimates the kinetics of the interaction as ka = (5.9 ±
1.1) × 104 M−1 s−1 and kd = (2.0 ± 1.9) × 10
−5 s−1. The error
associated with the dissociation rate constant is large due to
the apparently slow dissociation rate.
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The ϑm Fab, ϑm Fc, and ϑm antigen of all antibody samples and
their analytes binding to the Fab, Fc, and antigen assays were
estimated from binding data (Fig. 3) using the Langmuir
fitting routine and the values are listed in Table 1. All
ϑm estimates assume antibody concentrations stated in the
product data sheets which were confirmed as accurate by ab-
sorbance at A280 nm. The ϑm Fab is consistently lower than
the ϑm Fc for all antibody samples tested, indicating that for a
given surface area, more antibodies are adsorbed when bound
via the Fc region to the PAG surface compared to the antigen
surface. The therapeutic infliximab biosimilar antibody has a
particularly low ϑm Fab value indicating a low antigen binding
density or a low epitope presentation on the sensor surface.
An estimate of the relative binding site density differences
between PAG and the antigens may be obtained by comparing
the ϑm Fab/ϑm Fc ratio of the NISTmAb (0.26 ± 0.04) to that of
the panel of antibodies with a range = (0.004–1.1) × 10−3.
Furthermore, the ϑm antigen/ϑm Fc ratio of the antibody samples
is an estimate of antibody monomeric purity (related to moles/
moles), after normalizing for molecular mass by dividing
ϑm antigen and ϑm Fc by the antigen masses and intact IgG
masses respectively (Fig. 3i).
To validate the ϑm antigen/ϑm Fc ratio as a measure of antibody
monomeric purity, the biosensor results were compared with
results from the ESI mass spectrum recorded for each antibody
(see Electronic Supplementary Material (ESM) Fig. S1). The
deconvolved mass spectrum of the NISTmAb is dominated by
a species at 148.2 kDa attributed to the pure, non-fragmented
IgG structure. The NISTmAb Fab fragment has a reportedmass
of 47 (± 5) kDa [16] and the mass spectrum recorded here
Fig. 3 Biosensor analysis of antibody panel samples: a–h raw kinetic
response of the PAG surface (blue) and antigen surface (orange) to anti-
body binding (0–300 s) and antigen binding (400–700 s). i ϑm analysis
showing the ϑm Fab/ϑm Fc ratio (green) and the ϑm antigen/ϑm Fc ratio (gold).
The ϑm values of the ϑm antigen/ϑm Fc ratio are normalized for the mass of
the antigen and intact antibody derived from the ESI data. Error bars are
95% confidence intervals. The stoichiometric limit of the normalized
ϑm antigen/ϑm Fc ratio is between 1 and 2 (dashed lines).
Fig. 2 RI time dependence for the
NISTmAb binding to its antigen,
RVSF, immobilized on the sensor
surface: a kinetic response curves
obtained from 1.56, 3.23, and
6.25 (± 5%) nM NISTmAb
samples (grey), and global fit to
the Langmuir adsorption model
(red); b residuals over the time
course of the fit, showing consis-
tent error between model fit and
data; c histogram of the residuals
indicating the error between the
model fit and data is normally
distributed.
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shows a low intensity mass peak at 48 kDa. All antibody sam-
ples show additional lower mass proteins with varying abun-
dances attributed to any of the fragments shown in Fig. 1,
including dissociated heavy chain (Hc) and light chain (Lc).
The relative abundances of fragments relative to the intact an-
tibody (Fig. 4) are determined from the area-under-the-curve
(AUC) of regions in which masses are typically present: 140–
160 kDa, 90–110 kDa, 65–85 kDa, 40–60 kDa, and 15–
35 kDa. These regions of the mass spectrum correspond to
the predicted fragmentation products shown in Fig. 1.
TheHcLc fragment, expected at 75 kDa, is themost abundant
fragmentation product in all monoclonal antibody samples,
whilst the Fab-Fc fragment is most abundant in the polyclonal
samples, with the exception of anti-TBG. TheAUCof impurities
relative to the intact IgG AUC is < 20% for monoclonal antibod-
ies. In contrast, all polyclonal samples display impurities present
at > 20% relative to the intact IgG structure. The monomeric
purity estimated by ESI is the peak area of the intact region
expressed as a percentage of total peak area (area/area) and is
tabulated in Table 1, expressed as amean of 3mass spectra and a
95% confidence limit of ± 2%. The monomeric purity of the
NISTmAb is determined by ESI to be 94 ± 2% and compares
well to the reported value 97% by NIST [8].
Discussion
Antibody monomeric purity is critical for immunoassay de-
velopment, binding kinetics studies, and effective immuno-
therapy. The Fab assay provides data for kinetic analysis of
the antibody-antigen binding reaction, whilst the Fc and antigen
assays provide potential assays for the rapid assessment of
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Fig. 4 The abundances of fragments in each antibody sample evaluated
by taking the AUC of specific regions of the mass spectra corresponding
to IgG fragmentation products. The percentage abundances of the most
abundant peaks are plotted relative to the AUC of the intact region (140–
160 kDa): 90–110 kDa (light blue), 65–85 kDa (gold), 40–60 kDa (pink),
and 15–35 kDa (blue). All regions may contain Fc moieties.
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antibody monomeric purity. The Fc assay may identify low
monomeric purity based on a potential mass deficit observed
for fragmented samples binding to a constant number of bind-
ing sites on the PAG surface. The antigen assay assesses mo-
nomeric purity using the binding ratio of antigen to antibody
captured by the PAG surface. Results are validated using mo-
nomeric purity estimates from native ESI-QTOF mass
spectrometry.
ESI data suggest the most abundant glycoform of the
intact NISTmAb has a mean molecular mass of 148.2 kDa
and the sample displays a distinctive glycosylation pattern
in good agreement with published values [11]. The homo-
geneity of the NISTmAb contrasts with the heterogeneity
of intact IgG masses in the anti-C5a monoclonal, anti-
CRP monoclonal, and anti-CRP polyclonal samples, at-
tributed to multiple glycoforms (ESM Fig. S2) [24]. The
ESI data validate the NISTmAb as a good standard anti-
body of high monomeric purity. From the ESI mass spec-
trum data, the mean mass of proteins in the antibody sam-
ples, MESI, can be derived:
MESI ¼ aAþ bBþ cC þ dDaþ bþ cþ d ð3Þ
where lowercase letters represent the percentage AUC of
the mass spectrum relative to the intact peak area (140–
160 kDa) from the regions: 90–110 kDa (predicted Fab-Fc
complex), 65–85 kDa (predicted HcLc complex), 40–
60 kDa (predicted Hc or Lc), and 15–35 kDa (predicted
Lc or Hc monomer of Fc). Uppercase letters represent the
mean mass of the integration region. The derived MESI
values of each sample in the panel are shown in Table 1.
Themonomeric purity of the NISTmAb and the therapeutic
infliximab biosimilar is high, which is not the case for the
other commercially available samples that would be used for
research applications. The reliability of experiments involving
Western blots, immunohistochemistry, flow cytometry, and
immunoprecipitation is negatively impacted by variations in
antibody purity as these techniques fundamentally rely on a
connection between Fc and Fab regions of the antibody. The
consequence of purity on kinetic analysis also needs to be
considered with the fundamental errors of the 1:1 binding
model or Langmuirian kinetics conventionally used to analyse
antibody binding events. Fitting a set of low concentrations in
the global fit methodology typically produces an error of 15%
for ka and 10% for kd over the timescale of the experiments
[19]. Model fitting errors would dominate the analysis of the
NISTmAb and infliximab biosimilar samples but this
would not be true for all members of the antibody panel
tested here. For the case of the anti-TBG sample, any
reported antibody kinetics analyses without a sample
purity assessment and correction may have an error of
up to 45% due to low monomeric purity.
The packing density of IgG around a protein is a property
of epitope density, antibody conformation, and monomeric
purity. Antibodies with identical masses should achieve iden-
tical ϑm values for a given antibody binding density, albeit
after differing periods of time to allow variations in associa-
tion kinetics. There is significant variation in the ϑm Fab values
recorded (Table 1) which may be explained by variation in
availability of epitopes for antibody binding as evidenced by
the larger ϑm Fab of polyclonal anti-CRP compared to the
monoclonal anti-CRP sample on the same CRP surface. In
contrast, the ϑm Fc shows less variation than ϑm Fab, attributed
to the use of a common PAG surface for all antibody samples
with a consistent number of binding sites.
Variation in ϑm Fc may occur due to differing mean IgG
mass differences (monomeric purity differences) between IgG
samples as observed with ESI. The Fc assay presented here
will bind with high affinity to both intact IgG and the most
abundant fragmentation products which contain the Fc region
(Fig. 1), a concern for PAG-based affinity purification of an-
tibodies but a potential antibody fragmentation assay when
combined with surface plasmon technology. Any given ϑm
derived from fitting of the Langmuir equation (Eqs. 1 and 2)
may be related to the adsorbed mass on the surface,Madsorbed,
by de Feijter’s formula [25]:
M adsorbed ¼ dA ΔRIdn
dc
ð4Þ
where dA is the thickness of the adsorbed layer, dn/dc is the
rate of change of refractive index with surface concentration
(the refractive index increment), andΔRI is the change in the
refractive index recorded. The value of dn/dc has been mea-
sured for protein as 0.182 g cm−3 and has been shown to vary
with buffer conditions [26] but the effect is small [25].
The largest uncertainty in the estimate of Madsorbed is the
value of dA. IgG layers adsorbed onto protein A and silica
surfaces have been observed previously using ellipsometry
with thicknesses of 4 nm [27] to 16 nm [28] respectively.
Neutron reflectivity measurements of IgG4 binding to a pro-
tein A/BSA surface report three sequential layers leading to
total thicknesses between 6.1 nm and 25 nm depending on
washing and blocking of the surface [29] because non-
specific 3D aggregation at high IgG concentrations can enable
adsorbed layers to exceed the maximum length of a single IgG
molecule [30]. The mean cross-section dimension of the IgG
crystal structure [31] suggests a dA of 10 nm, assumed con-
stant for all antibody samples here. The derived surface
adsorbed mass density therefore depends only on the differ-
ence in the refractive index (ΔRI) of the adsorbed antibody.
Substituting ϑm Fc of NISTmAb for ΔRI in Eq. 4 predicts
the areal density of the NISTmAb on the PAG surface,
Madsorbed = 3.7 ± 0.5 × 10
−8 g cm−2. By comparison, electro-
static adsorption of monoclonal antibodies onto a variety of
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surfaces has been reported at densities in the range 5 × 10−7 to
5 × 10−6 g cm−2 [32, 33]. Electrostatic adsorption is expected
to achieve a higher surface mass density compared with the
ordered two-dimensional layer of IgG bound to a PAG sur-
face. The Madsorbed values of each antibody studied are pre-
sented in Table 1.
The ESI data indicate a high monomeric purity in the
NISTmAb sample (94% ± 2) with an intact mass, Mmonomer,
of 148.2 kDa. The NISTmAb data and the Avogadro constant,
NA, can be used to calibrate the surface density of antibodies
bound at saturation, NAb =Madsorbed ×NA/Mmonomer = (1.49 ±
0.21) × 1011 cm−2. Comparatively, the maximum number of
monoclonal antibodies in a monolayer has been determined
by adsorption onto a silicon nitride surface as 1.2 × 1012 cm−2
[34]. The unknown purity of antibody samples in the literature
is a potentially large source of error for published NAb values
derived from protein mass density measurements. The NAb
figure presented here is of known accuracy due to the mono-
meric purity estimate from ESI.
The number of PAG binding sites on the surface is constant
for NISTmAb and if all antibodies bind to the surface with the
same packing density then an estimate of effective mass at
each binding site may be estimated from a simple ratio:
ϑFcm ¼ ϑmonomerm 
MFc
Mmonomer
ð5Þ
where ϑmonomerm and Mmonomer are the ϑm Fc and mass of the
monomeric reference material, which in the present study is
the NISTmAb with ϑm Fc = 6.66 ± 0.96 mRIU and a mass of
148.2 kDa.When an antibody sample has degraded, a fraction
of Fc binding domains on the PAG will be occupied by anti-
body fragments with a lower mean molecular mass than the
intact IgG reference and will exhibit a lower ϑm Fc for a con-
stant number of occupied binding sites. The Fc assay can be
used to estimate monomeric purity by expressing MFc as a
percentage of Mmonomer (Table 1).
Aweak positive correlation is observed between ϑm Fc and
ESI monomeric purity and several phenomena may account
for the variations observed in ϑm Fc. Firstly, NAb at ϑm Fc may
be a fundamental property of a given antibody due to glycan
variation and the locations of PAG binding domains on the
structure, leading to some antibody monomers binding in ori-
entations which favour closer packing on the surface [35]. The
ϑm Fc will also be sensitive to non-specific aggregation and
clustering of IgG [29], although aggregates of the NISTmAb
IgG are only observed following deliberate physical agitation
for days at room temperature [36] and the antibody samples
tested here are not expected to contain significant aggregates
due to appropriate storage. The lack of correlation between
ϑm Fc and ESI monomeric purity may best be explained by
the orientation and higher packing density of low mass anti-
body degradation products, which may have access to a great-
er number of binding sites on the PAG surface than
monomeric IgG [20]. Therefore, it is likely that the ϑm Fc of
the Fc assay is only sensitive to severe antibody degradation.
Our results show that a more sensitive measure of mono-
meric purity is to support antibodies on the PAG surface and
measure the antigen binding ratio, ϑm antigen/ϑm Fc, which after
normalizing for molecular mass, shows a strong dependence
on monomeric purity estimated by ESI (Fig. 5).
The infliximab biosimilar antibody binds to a relatively
low mass antigen (TNFα with a monomer mass of 17 kDa)
and displays an antigen-antibody binding ratio of 1.71 ± 0.16.
The NISTmAb binds to a higher-mass antigen (53 kDa) and
displays a lower antigen-antibody binding ratio of 1.31 ± 0.57
attributed to greater steric hindrance of antigens. The
ϑm antigen/ϑm Fc ratio threshold to determine monomeric purity
of antibody samples is antigen-dependent for larger antigens
but would always exceed 1 with adequate antibody spacing on
a plasmonic surface. The NISTmAb performs well as a stan-
dard material for the antibodies shown, but calibration of the
assay would likely be improved by comparing each tested
sample to a high-purity reference standard which binds to a
common antigen.
Of the commercially available research antibodies, anti-
TBG antibody shows a relatively high ϑm Fab/ϑm Fc ratio but
displays the weakest ϑm antigen/ϑm Fc ratio. These two ratios
indicate that both Fab and Fc regions of TBG are present in the
sample, but a significant proportion is separated due to
Fig. 5 The relationship between monomeric purity estimated from the
ESI data and the mass -normalized ϑm antigen/ϑm Fc biosensor measure-
ment. The NISTmAb and infliximab biosimilar (green) are > 90% pure
according to ESI data and exhibit ϑm antigen/ϑm Fc ratios within the expect-
ed limits of between 1 and 2 antigens per antibody. Other commercially
available antibodies (red) are < 90% pure and show less than 1 antigen
bound per antibody. A 5-parameter logistic curve fits well to the data
(blue) and is constrained by a maximum asymptote of 2 (the upper limit
of the antigen-antibody interaction stoichiometry). The anti-TNFα poly-
clonal (orange) does not fit the trend line, likely due to a unique fragmen-
tation pattern resulting in a majority of 100 kDa HcLc fragments which
may pack tightly on the PAG surface and remain capable of binding 1
antigen
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degradation. The high fragmentation of the anti-TBG anti-
body is supported by the lack of intact antibody in the ESI
mass spectrum (ESM Fig. S1).
The ϑm antigen/ϑm Fc ratio is a measure of the biological
activity of an antibody sample, whereas the ESI monomeric
purity estimated from mean mass penalizes any form of anti-
body fragmentation. The ESI data predict a low monomeric
purity in the anti-TNFα polyclonal but the sample displays a
relatively high ϑm antigen/ϑm Fc ratio. The result may be ex-
plained by the unique degradation pattern shown in Fig. 4
which indicates that the most abundant species is the
100 kDa HcLc fragment which is capable of binding to PAG
and one antigen. The fragmentation in the anti-TNFα poly-
clonal remains identifiable by comparison to the infliximab
biosimilar which shares the same antigen but exhibits a higher
antigen-antibody binding ratio.
Using the ϑm Fab/ϑm Fc ratio recorded by the biosensor, the
antibody panel readily divides into two types of samples: the
high-purity (> 90%) samples (NISTmAb and infliximab
biosimilar) and the remainder of the panel with lower
monomeric purity (< 90%). The ϑm Fab/ϑm Fc ratio is signifi-
cantly different for these two material types as evidenced by a
two-sample t test and two-sample Kolmogorov-Smirnov (P =
0.01 and P = 0.03 respectively). The assays developed here
show the potential to test the specification of antibodies im-
mediately before use as assay materials and in other antibody-
dependent techniques to prevent variability in experimental
results caused by sample degradation. Both the ESI and
biosensor-based assays provide an estimate of monomeric pu-
rity in 15 min but the biosensor platform exhibits some key
advantages. The biological activity of therapeutic antibody at
both the Fab and Fc regions is critical and can be tested on the
small form factor multiplexed biosensor platform when reli-
ably calibrated using the reference NISTmAb.
Conclusions
The NISTmAb provides an important new benchmark mate-
rial which enables the calibration of biosensors assessing mo-
nomeric purity of antibody samples with assays for Fab, Fc,
and antigen. The analysis of a panel of commercially available
research grade antibodies, using ESI and biosensor surfaces,
highlights significant variation in monomeric purity and raises
accuracy concerns for previously reported ka, kd, and KD mea-
surements of similar materials in the literature and the risk to
reproducibility. Without sample monomeric purity analysis
(of both the antibody and the antigen) these measurements
may have errors approaching 50% in highly fragmented sam-
ples. The biosensor-based technique presented here to esti-
mate antibody monomeric purity can be performed in
15 min and may be combined with additional rapid tests for
IgG aggregates as described for the NISTmAb in ref. [36].
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